RELMADA THERAPEUTICS, INC.
No SEC Form 4 filings for $RLMD in the last 30 days.
See all $RLMD insider activity →RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030099301ex99-1.htm PRESS RELEASE DATED AUGUST 6, 2026, REGARDING A CORPORATE UPDATE AND REPORTING ITS FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2026 Exhibit 99.1 Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Busin
Relmada Therapeutics (NASDAQ:RLMD) reported Q1 2026 results on May 12, citing positive 12-month Phase 2 data for NDV-01 in high-risk non-muscle invasive bladder cancer, with a 95% complete response rate, according to the company. It said it has $234 million cash and a $160 million financing, expected to fund operations through 2029, including a Phase 3 RESCUE program starting mid-2026.
MarketBeat compared Relmada Therapeutics (NASDAQ:RLMD) and Clearmind Medicine (NASDAQ:CMND). RLMD has a consensus target price of $12.00 (67.95% upside) versus CMND’s lower outlook, and RLMD is trading at a lower P/E. Institutional ownership is 45.2% for RLMD and 96.1% for CMND; beta is 0.43 for RLMD and 0.87 for CMND.
Over the past 7 days, alphai's AI scored 1 news story mentioning RLMD (RELMADA THERAPEUTICS, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent RLMD coverage spans financial news, earnings and technology.
Near-term catalyst is execution toward year-end IND submissions and subsequent Phase 3 RESCUE start; cash runway extends to 2029, reducing immediate financing risk.
Clinical update and funding runway details support a near-term catalyst into the AUA meeting and Phase 3 initiation timing.
Relative-valuation/analyst-target framing may support incremental bullish positioning in RLMD, but it’s not a new catalyst.
Relmada Therapeutics (RLMD) has announced promising Phase 2 data for NDV-01 and plans for Phase 3, supported by significant funding. The stock has a bullish sentiment with potential for short-term gains, especially among traders focusing on biotech catalysts.
The upgrade of Relmada Therapeutics (RLMD) by Leerink Partners, coupled with increased institutional ownership and bullish sentiment, suggests a positive short- to medium-term outlook for the stock.
alphai scores every news story that mentions RLMD with an AI model for sentiment and relevance, and aggregates insider trades from RELMADA THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030099301ex99-1.htm PRESS RELEASE DATED AUGUST 6, 2026, REGARDING A CORPORATE UPDATE AND REPORTING ITS FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2026 Exhibit 99.1 Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Busin
6 min readRelmada Therapeutics (NASDAQ:RLMD) reported Q1 2026 results on May 12, citing positive 12-month Phase 2 data for NDV-01 in high-risk non-muscle invasive bladder cancer, with a 95% complete response rate, according to the company. It said it has $234 million cash and a $160 million financing, expected to fund operations through 2029, including a Phase 3 RESCUE program starting mid-2026.
3 min readMarketBeat compared Relmada Therapeutics (NASDAQ:RLMD) and Clearmind Medicine (NASDAQ:CMND). RLMD has a consensus target price of $12.00 (67.95% upside) versus CMND’s lower outlook, and RLMD is trading at a lower P/E. Institutional ownership is 45.2% for RLMD and 96.1% for CMND; beta is 0.43 for RLMD and 0.87 for CMND.
4 min readRelmada Therapeutics announced strong 12-month Phase 2 data for NDV-01 in bladder cancer, with complete response rates up to 95% and durable responses up to 80% at 12 months. The company plans to launch its Phase 3 RESCUE program in mid-2026 and has secured $234 million in funding, ensuring operations through 2029 despite increased quarterly net losses. An analyst has rated RLMD stock as a Buy with a $19.00 price target.
3 min readLeerink Partners has upgraded Relmada Therapeutics (RLMD) from Market Perform to Outperform, with an average one-year price target of $10.20 per share, suggesting a 160.54% upside. Institutional ownership in RLMD increased by 49.27% in the last quarter, and the put/call ratio indicates a bullish outlook for the company.
3 min readImage source: The Motley Fool.Thursday, November 13, 2025 at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
3 min readCORAL GABLES, Fla., Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- Relmada Therapeutics, Inc. ( Nasdaq: RLMD, "Relmada" or the "Company" ) , a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference ...
3 min readCORAL GABLES, Fla., Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- Relmada Therapeutics, Inc. ( Nasdaq: RLMD, "Relmada" or the "Company" ) , a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the pricing of its ...
2 min readAnnounces NDV-01 9-Month Follow-up Safety and Efficacy Data in ...
2 min readCORAL GABLES, Fla., Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- Relmada Therapeutics, Inc. ( Nasdaq: RLMD, "Relmada" or the "Company" ) , a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous system indications, today issued a Letter to ...
3 min read
